Clinical trials

#Biotechnology #Clinical trials #Data #Microbiology #Pharmaceuticals

Cardiac patients receiving nasal gel showed reduction of S. aureus

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has released data from its recent Phase IIb clinical trial. In March 2021, the company announced that this study had met its primary endpoint, demonstrating a reduction of 2.5 log… Read More

#News

#Clinical trials #Covid-19 #Drug design #Drug development #Drug discovery

ACRO releases toolkit to help advance decentralised clinical trials

The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs… Read More

#News

#Awards #Biopharmaceuticals #Biotechnology #Clinical trials

Frost & Sullivan announces DCT award winner 

Thread, a technology and service provider for decentralised clinical trials, has been awarded a Frost & Sullivan award. The company scooped the Frost & Sullivan’s 2021 Customer Value Leadership Award in the decentralised clinical trials industry. “Thread’s innovations via its decentralised trials platform are sure… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (19 – 23 July)

News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia… Read More

#News #Trending News

#Biosciences #Clinical trials #Drug delivery #Drug discovery #High throughput screening #Therapeutics

Mini-library approach delivers an arsenal in drug development pipeline

Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than… Read More

#Editor's Choice #Exclusive Content #News

#3D modelling #Clinical trials #Drug development #Drug discovery

Lonza and CN Bio hepatocyte distribution agreement

Lonza and CN Bio have entered into a distribution agreement where Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in its PhysioMimix Single-and Multi-Organ MPS. The aim is to change the way human-relevant pre-clinical data is generated. With prequalified cells, customers can… Read More

#News

#Awards #Clinical trials #Covid-19 #Data #Drug discovery #Immunology / Virology & Vaccines

Breakthrough Therapy Designation for single-shot chikungunya vaccine

Vaccine development company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA). Breakthrough Therapy Designation intends to facilitate and expedite development and review of new drugs for serious or life-threatening conditions where preliminary clinical data demonstrates that… Read More

#Editor's Choice #News

#Clinical trials #Events #Therapeutics

Ilya Pharma at US Military Health System Research Symposium

Ilya Pharma has been invited to present its ILP100 accelerated wound healing therapy at the US Military Health System Research Symposium (MHSRS) 2021, to be held August 23-26 at the Gaylord Convention Center in Florida. Results for the company’s first in human trial were released earlier this year and… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Tumour biology

First patient dosed with Gadeta’s gamma delta TCR cell therapy

Gadeta, a clinical-stage company developing gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, has announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer. The multicentre Phase I/II study in collaboration with the Dana-Farber Cancer Institute,… Read More

#Cancer Research #News

Cannabis plant
#Cannabinoid #Clinical trials #Drug development #Drug discovery

Agreement will speed up cannabinoid drug development

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Biotechnology #Biotherapeutics #Clinical trials #Therapeutics

Starton Therapeutics features on Amazon Prime ‘Unicorn Hunters’

‘Unicorn Hunters’ is a new show on Amazon Prime which invites viewers around the world to invest alongside a panel of entrepreneurs and business leaders. It aims to level the field for start-ups who do not have access to traditional venture capital funding. The panel includes Steve Wozniak (Co-founder of… Read More

#News

#Cell and gene therapy #Clinical trials #Diabetes

Phase II gene therapy study approved for difficult diabetic wounds

Ilya Pharma has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds (EudraCT 2021-000563-69). ILP100h has recently been assigned the INN name emilimogene sigulactibac by the World… Read More

#News

#Clinical trials #Drug development #Drug discovery #Research #Sclerosis

Gesynta Pharma announces significant progress across new drug candidate

Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More

#News

#Clinical trials #Immunology / Virology & Vaccines #Malaria #Vaccines

Investigational malaria vaccine gives strong, lasting protection

Two US Phase I clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. Read More

#News

#Clinical trials #Drug development #Drug discovery

163% growth in recruiting clinical trial sites in China

Virtual clinical development specialist Phesi has released its analysis of the growth in recruiting clinical trial sites in China since the beginning of 2018. The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021. While… Read More

#News